baby step toward improving crizotinib therapy in the clinic. a performed to find the maximum tolerated dose in the pediatric population, this mechanistic study provides more than mutation. Although careful toxicity studies need to be ALK should improve therapy for patients with this common ALK. These observations suggest that either increasing the dose of crizotinib or engineering higher-affinity inhibitors therapy, respectively. This reduced sensitivity was caused by a heightened ATP-binding affinity in F1174L-mutated mutations, F1174L and R1275Q, are unresponsive to and effectively inhibited by crizotinib ALK most common two substrate. The authors used human neuroblastoma cell lines and xenografts in mice to show that cancers with the Activating mutations in the anaplastic lymphoma kinase (ALK) gene were recently discovered in neuroblastoma, a cancer of the developing autonomic nervous system that is the most commonly diagnosed malignancy in the first year of life. The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor. Identification of ALK as an oncogenic driver in neuroblastoma suggests that crizotinib (PF-02341066), a dual-specific inhibitor of the ALK and Met tyrosine kinases, will be useful in treating this malignancy. Here, we assessed the ability of crizotinib to inhibit proliferation of neuroblastoma cell lines and xenografts expressing mutated or wild-type ALK. Crizotinib inhibited proliferation of cell lines expressing either R1275Q-mutated ALK or amplified wild-type ALK. In contrast, cell lines harboring F1174L-mutated ALK were relatively resistant to crizotinib. Biochemical analyses revealed that this reduced susceptibility of F1174L-mutated ALK to crizotinib inhibition resulted from an increased adenosine triphosphatebinding affinity (as also seen in acquired resistance to epidermal growth factor receptor inhibitors). Thus, this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.
INTRODUCTION
Neuroblastoma arises in the developing autonomic nervous system and is the most commonly diagnosed malignancy in the first year of life. The disease shows a wide range of clinical phenotypes: Although tumors regress spontaneously in some patients, most have aggressive metastatic disease (1) . Neuroblastoma remains a leading cause of childhood cancer mortality despite marked escalations in dose-intensive chemoradiotherapy, and long-term survivors experience significant treatment-related morbidity (2) .
One promising therapeutic target in neuroblastoma is the anaplastic lymphoma kinase (ALK), an orphan receptor tyrosine kinase (RTK) normally expressed only in the developing nervous system (3) . Oncogenic ALK alterations were first described in anaplastic large cell lymphoma (4) , where a chromosomal translocation leads to production of a fusion protein with the ALK intracellular region fused to an N-terminal fragment of nucleophosmin (NPM). Other ALK fusion proteins are potent oncogenic drivers in a subset of nonsmall cell lung cancers (NSCLCs) (5) and drive inflammatory myofibroblastic tumors (IMTs) as well as other cancers (6) . In neuroblastoma, germline activating point mutations in the intact ALK gene were revealed by linkage analysis of a set of families with highly penetrant autosomal dominant disease (7) . In addition, somatic ALK mutations were found in~10% of sporadic neuroblastoma cases (7) (8) (9) (10) (11) . The most frequently observed substitutions, together accounting for >80% of sporadic ALK mutations in neuroblastoma samples (12) , were F1174L and R1275Q, which lie in key regulatory regions of the ALK receptor kinase domain. Mutations in the intact ALK gene have also recently been reported in anaplastic thyroid cancer (13) .
ALK tyrosine kinase activity can be inhibited by crizotinib (PF-02341066), a small-molecule adenosine triphosphate (ATP)-competitive inhibitor that selectively targets both the ALK and the Met RTKs (14) . A recent phase 1 study of crizotinib demonstrated safety and tolerability in humans, as well as tumor shrinkage or stable disease in most patients with ALK-dependent NSCLC (15) . Crizotinib is also in early-phase clinical testing in patients with neuroblastoma. As with other tyrosine kinase inhibitor therapies, acquired resistance to crizotinib is already beginning to emerge (16) (17) (18) . Understanding how mutations affect both kinase activity and inhibitor sensitivity is imperative for guiding future clinical use of ALK-targeted inhibitors. Here, we explored the ability of crizotinib to inhibit intact ALK in neuroblastoma cell line models and analyzed the effects of the two most common activating mutations seen in neuroblastoma on ALK's tyrosine kinase activity. We found that the F1174L mutation, although activating, reduced ALK sensitivity to crizotinib in xenograft, cell line, and enzymatic assays, consistent with the recent surprising report of this mutation as an acquired resistance mutation in an oncogenic ALK fusion protein (17) . Compared with the R1275Q activating mutation, we found that an F1174L substitution increased ATP-binding affinity, leading to crizotinib resistance that should be surmountable with higher doses of crizotinib or new higher-affinity inhibitors.
RESULTS
The effect of crizotinib on growth of neuroblastoma-derived cell lines depends on ALK genomic status and the specific mutation To assess how the most common ALK mutations in neuroblastoma (F1174L and R1275Q) affect intrinsic ALK activity, we expressed fulllength ALK variants in human retinal-pigmented epithelial (RPE) cells immortalized with telomerase reverse transcriptase (hTERT-RPE1). We selected RPE cells because they are derived from human neural crest-like neuroblastomas but express no endogenous ALK (Fig. 1A) . Whereas wild-type ALK expressed in hTERT-RPE1 cells was not detectably phosphorylated (Fig. 1A) , both R1275Q-and F1174L-mutated ALK showed robust autophosphorylation in immunoblots using an ALK pY1604-specific antibody, regardless of the presence of serum in the medium (Fig. 1A , middle panels). Thus, both common neuroblastoma mutations caused constitutive ALK activation to similar extents, as seen in Ba/F3 (10) , NIH3T3 (9, 19) , and PC12 cells (20) , as well as in numerous neuroblastoma-derived cell lines (7, 10, 11, 19) . Consistent with previous reports (19, 21) , two ALK species were always observed. Full-length ALK migrates as a 220-kD protein, and the 140-kD species is a cleavage product lacking part of the extracellular region (21) .
We and others have shown that RNA interference (RNAi) knockdown of ALK, or pharmacological inhibition of ALK kinase activity, has an antiproliferative effect in several ALK-mutated neuroblastoma cell lines (7, (9) (10) (11) , associated with G 1 arrest and increased apoptosis (10) . To exploit this observation clinically, we assessed the cytotoxicity of the ALK/Met inhibitor crizotinib (PF-02341066) in cell models for neuroblastoma. We first analyzed the ability of crizotinib to inhibit substrate-adherent growth of a panel of 18 human neuroblastomaderived cell lines. The 18 cell lines were chosen to represent ALK genomic status in primary tumors, and have all previously been well characterized. Analysis of concentration-response curves across a fourlog crizotinib dose range (1 to 10,000 nM) revealed significant differences in IC 50 (median inhibitory concentration) that correlated with ALK status. As illustrated in Fig. 1B , cell lines harboring an ALK aberration (amplification or mutation) were significantly more sensitive to growth inhibition by crizotinib than those with wild-type ALK status (P = 0.001, two-sided exact Wilcoxon-Mann-Whitney test). To ensure that crizotinib cytotoxicity in this assay reflected ALK inhibition, we confirmed that the drug reduced phospho-ALK (pALK) levels (see below). In addition, because crizotinib also inhibits Met kinase activity (14) , it was important to exclude Met inhibition as a mechanism. We confirmed that none of the crizotinib-inhibited neuroblastoma cell lines displayed significant phospho-Met levels ( fig. S1 ). Moreover, RNAi knockdown of Met in a panel of cell lines with altered ALK genomic status had no growth-inhibitory effect (table S1). The enhanced crizotinib sensitivity of almost all neuroblastoma cell lines harboring ALK mutation or amplification (Fig. 1B) strengthens the argument for ALK inhibition as a useful therapeutic strategy in neuroblastoma.
Mutation-specific stratification of crizotinib sensitivity in neuroblastoma cell lines (Fig. 1B) may have significant implications for clinical use of this drug. Cell lines expressing F1174L-mutated ALK were marginally significantly less sensitive to growth inhibition by crizotinib than those expressing R1275Q-mutated ALK (P = 0.067, two-sided exact Wilcoxon-Mann-Whitney test), justifying further investigation. This result was initially unexpected, because the F1174L and R1275Q mutations appear to promote similar degrees of constitutive ALK activation (Fig. 1A) , and small interfering RNA (siRNA) knockdown of either variant inhibits growth of the relevant cell lines (7) . Assuming a similar oncogenic driver role for both ALK variants, the data in Fig. 1B suggest that the F1174L mutation may also promote crizotinib resistance. Indeed, an F1174L mutation was recently found to cause acquired crizotinib resistance in a patient with an IMT driven by constitutively active RANBP2-fused ALK (17) . The F1174L substitution may therefore combine the characteristics of an activating Growth inhibition ± SD is reported for at least three independent experiments. P values were calculated for marked comparisons with twosided exact Wilcoxon-Mann-Whitney tests. Cell lines were as follows (left to right): WT ALK-amplified (NB1); R1275Q (NB1643, LAN5); F1174L (SH-SY5Y,  KELLY, NBSD, SMS-SAN); WT ALK, normal copy number (NB1691, NB-EBc1,  IMR5, NB16, NLF, IMR32, NBLS, SKNBE2C, NGP, SKNAS, SKNFI) . mutation and a resistance mutation, understanding of which is crucial for developing ALK-targeted therapy.
Tumor growth driven by F1174L-mutated ALK also shows reduced sensitivity to crizotinib in vivo Using xenograft models of neuroblastoma, we next asked whether the two ALK variants show differential crizotinib sensitivity in vivo. We tested a pharmacologically relevant crizotinib dose (100 mg/kg per day for 4 weeks) against serially passaged human neuroblastoma cells xenografted in the flank of CB17 immunodeficient mice (14) . As shown in Fig. 2A , crizotinib caused tumor regression within 3 weeks in all NB1643 xenografts (R1275Q-ALK), and complete regression was sustained over the fourth week of dosing (P < 0.0001). Assessment of pALK levels by immunoblotting NB1643 xenograft lysates harvested after 48 hours of crizotinib administration (4 hours after final dose) confirmed inhibition of ALK phosphorylation ( Fig. 2A,  inset) . Consistent with the differential sensitivity suggested in vitro, xenografts harboring F1174L-ALK (SH-SY5Y and NBSD) were substantially less responsive to crizotinib. No tumor regression was observed in crizotinib-treated SH-SY5Y xenografts (Fig. 2B ), although tumor growth was significantly delayed (P < 0.0001) and the time taken to reach the study endpoint (tumor volume ≥1.5 cm ) was extended by an average of 7.7 days (P < 0.0001). Crizotinib also failed to reduce tumor volume (P = 0.29) in NBSD (F1174L) xenografts (Fig.  2C) , although the time to reach the study endpoint was again extended by a mean of 3.7 days (P = 0.04). These results argue that tumors driven by F1174L-mutated ALK are significantly less sensitive to crizotinib in vivo. Crizotinib treatment led to complete tumor regression in NB1 xenografts with amplified, overexpressed wild-type ALK (Fig. 2D ), but not in NB-EBc1 or SKNAS xenografts that have no amplification (Fig. 2, E and F) . Crizotinib treatment delayed tumor growth (P < 0.0001) in NB-EBc1 xenografts (low pALK levels, but no mutation or amplification), but had no detectable effect (P = 0.70) in SKNAS xenografts, which express low levels of wild-type ALK and show no detectable pALK (Fig. 2F) .
The F1174L mutation reduces crizotinib sensitivity of ALK autophosphorylation The reduced crizotinib sensitivity of cell lines and xenografts harboring F1174L-mutated ALK prompted us to analyze the effects of this drug on constitutive ALK activity in representative cell lines: NB1643 cells (which express R1275Q ALK) and SH-SY5Y cells (which express F1174L ALK). Crizotinib treatment abrogated Y1604 phosphorylation of ALK in both cell lines, but at different doses (Fig. 3) . In NB1643 (R1275Q) cells, ALK phosphorylation was essentially abolished at 100 nM crizotinib (IC 50 ,~10 nM), whereas complete inhibition of F1174L ALK phosphorylation in SH-SY5Y cells required almost 1 mM crizotinib (IC 50 ,~50 nM). Akt phosphorylation followed similar trends ( fig. S2 ), consistent with a previous report that ALK inhibition promotes apoptosis in neuroblastoma cell lines (10) . Crizotinib resistance of cells harboring the ALK F1174L mutation therefore appears to arise from less potent inhibition of constitutive ALK activity and thus of downstream survival signaling.
F1174L and R1275Q mutations promote autophosphorylation of the ALK kinase domain To understand why F1174L-and R1275Q-mutated ALK have different crizotinib sensitivities and how the mutations enhance kinase activity, we turned to in vitro studies of the ALK tyrosine kinase domain (ALK-TKD), purified from baculovirus-infected Sf9 cells as a hexahistidine-tagged protein. To generate fully dephosphorylated (inactive) ALK-TKD, we used YopH phosphatase treatment to reverse spontaneous autophosphorylation arising during production (Supplementary Methods). For comparative studies, fully autophosphorylated ALK-TKD was generated by clustering the protein on lipid vesicles bearing NTA-Ni head groups (DOGS-NTA-Ni), thus imitating ligandinduced ALK dimerization. This method has been used to promote assembly and activation of other receptor fragments, including epidermal growth factor receptor (EGFR)-TKD (22, 23) , and markedly enhances the rate of ALK-TKD autophosphorylation (Fig. 4A) .
Our initial investigations with MnCl 2 -containing assay conditions used in previous ALK-TKD studies (24) (25) (26) suggested only a threefold increase in kinase activity upon autophosphorylation. This contrasts starkly with the~100-to 200-fold activity increase typically seen upon activation loop autophosphorylation of other kinases from the insulin receptor (IR) family (27) (28) (29) . The anomaly arises because the previously used high (nonphysiological) Mn 2+ concentrations both increase unphosphorylated ALK-TKD activity ( fig. S3 , A to C)-as reported for other RTKs (30, 31)-and reduce activity of fully autophosphorylated ALK-TKD ( fig. S3D ). We therefore used a more physiological 10 mM MgCl 2 in subsequent studies (and no Mn 2+ ). Under these conditions, autophosphorylation promoted strong ALK-TKD activation (see below), as did the F1174L and R1275Q mutations ( Fig. 4B  and fig. S3E ).
Native gel electrophoresis (Fig. 4B) showed that autophosphorylation of dephosphorylated ALK-TKD was substantially accelerated by the F1174L and R1275Q mutations, confirming that these mutations activate the isolated kinase domain. Mobility of ALK-TKD in native gels was increased by autophosphorylation, with successive autophosphorylation events giving rise to four differently phosphorylated species over a period of 0.5 to 20 min at 37°C. Whereas unphosphorylated wild-type ALK-TKD was still detectable in Fig. 4B after 4 min, this species disappeared completely within 1 min for both mutated forms. Similarly, the first pALK-TKD species persisted until at least 8 min for wild-type protein, but only until~2 min for F1174L ALK-TKD and~3 min for R1275Q ALK-TKD. These results are shown graphically in fig. S4 . Using analytical ultracentrifugation, we ruled out the possibility that increased dimerization of mutated TKDs enhances their autophosphorylation ( fig. S5 ). ALK-TKD remained monomeric in solution regardless of mutation. The increased ALK-TKD autophosphorylation rates promoted by the F1174L and R1275Q mutations therefore reflect elevated basal kinase activity.
Wild-type and mutated ALK-TKDs have similar inhibitor selectivity profiles The relative crizotinib resistance of F1174L-mutated ALK observed in cell-based and xenograft studies prompted us to compare its inhibitor selectivity profile with those of wild-type and R1275Q-mutated ALK. We reasoned that the F1174L mutation might alter the drugbinding site so that certain ATP-competitive compounds (such as crizotinib) are less effective inhibitors of this variant than of R1275Q or wild type. To establish inhibitor selectivity profiles for wild-type, F1174L, and R1275Q ALK-TKD, we assessed the ability of overlapping panels of 320 well-characterized kinase inhibitors to inhibit their in vitro autophosphorylation (see the Supplementary Methods). As shown in fig. S6 , the inhibition profile of F1174L-mutated ALK-TKD was essentially identical to those for wild-type and R1275Q-mutated ALK-TKD. Thus, the F1174L mutation does not appear to change the relative abilities of different inhibitors to bind ALK-TKD. Autophosphorylation alone is sufficient for maximal ALK-TKD activation To better understand the reduced crizotinib sensitivity of F1174L-mutated ALK, we analyzed kinase activity more quantitatively. As a baseline for these studies, it was important first to establish the full range of wild-type ALK-TKD activity levels-in fully activated and unactivated states, respectively. We monitored tyrosine phosphorylation of a peptide corresponding to the ALK activation loop, with sequence ARDIYRASYYRKGGCAMLPVK ["YYY" peptide (25) ]. Table 1 lists kinetic parameters (k cat , K m, peptide , and K m, ATP ) for wild-type ALK-TKD in both inactive (unphosphorylated) and activated (fully autophosphorylated) states.
As shown in Fig. 4C and Table 1 , autophosphorylation elevated ALK-TKD catalytic efficiency primarily through a 45-fold increase in k cat (P < 0.0001), from 9.32 ± 0.85 min −1 (unphosphorylated) to 424 ± 63 min −1 (fully phosphorylated), accompanied by a 1.6-fold decrease in K m, peptide . Values for K m, ATP were higher than reported from Mn 2+ -containing assays (24-26) and were not significantly altered by ALK-TKD autophosphorylation (Table 1 and Fig. 4D ). This contrasts with other RTKs, where activation loop autophosphorylation reduces K m for both peptide and ATP substrates under similar (MnCl 2 -free) assay conditions (28, 29, 32) . Unlike other members of its family, ALK therefore does not appear to be autoinhibited by pseudosubstrate-like interaction of its unphosphorylated activation loop with the active site.
Although autophosphorylation increases ALK-TKD activity, we wondered whether TKD dimerization might play an additional allosteric activating role, as seen with EGFR (23). Whereas clustering EGFR-TKD on the surface of vesicles containing DOGS-NTA-Ni lipids promoted significant activation (Fig. 4E ), no activating effect was seen when fully phosphorylated pALK-TKD was similarly treated (Fig. 4F ). These data argue against an allosteric activation mechanism for ALK and suggest that autophosphorylation is sufficient for its maximum activation.
F1174L and R1275Q mutations constitutively activate ALK-TKD and display different kinetic profiles As reported in Table 1 , the F1174L and R1275Q mutations both cause significant increases in k cat even without autophosphorylation. The F1174L mutation increased k cat by~40-fold (P = 0.0013) to 365 ± 61 min −1 , close to the maximum measured for fully phosphorylated wildtype protein. The R1275Q mutation had a more modest effect, increasing k cat of unphosphorylated ALK-TKD by just 12-fold (P = 0.0001). Whereas the R1275Q mutation left K m, peptide unaltered, the F1174L mutation increased K m, peptide by about threefold. These two neuroblastoma mutations therefore promoted similar (10-fold) increases in catalytic efficiency (k cat /K m, peptide ) of unphosphorylated ALK-TKD ( Fig. 5A and Table 1 ) in the presence of saturating ATP. Autophosphorylation further increased catalytic efficiency (k cat /K m, peptide ) for both R1275Q and F1174L ALK-TKD variants (Fig. 5E ). For R1275Q, this resulted largely from an increase (about threefold) in k cat . For F1174L, phosphorylation reduced K m, peptide by about sevenfold (Table 1 ). In addition to being constitutively activated, F1174L ALK-TKD may be slightly "superactivated" upon full autophosphorylation for the particular peptide substrate used here (Fig. 5B) , with a catalytic efficiency that was~30% higher than measured for wild-type (P = 0.0342) or R1275Q (P = 0.0327) pALK-TKD.
Reduced K m for ATP explains the relative resistance of F1174L-mutated ALK to crizotinib The K m, ATP values listed in Table 1 (and Fig. 5C ) suggest one explanation for the reduced crizotinib sensitivity of cell lines and xenografts expressing F1174L-mutated ALK. K m, ATP for the F1174L mutant was 2.3-fold lower than that of R1275Q (P = 0.0007) when autophosphorylated (Fig. 5, D and F) , and 2.6-fold lower (P = 0.0045) in the dephosphorylated form (Fig. 5, C and F ). This trend was maintained when the assay was repeated at a higher peptide concentration of 2 mM ( fig. S7 and table S2 ). These data suggest that the F1174L mutation enhances the ATP-binding affinity of ALK, which in turn will reduce potency of any ATP-binding site competitor (such as crizotinib) at cellular ATP concentrations, as seen for drug resistance mutations in some other RTKs (33) .
To test this hypothesis, we compared the in vitro crizotinib sensitivity of the recombinant ALK-TKD variants at two different ATP concentrations (Fig. 5, G and H) . At 0.2 mM ATP (significantly lower than cellular levels), IC 50 values (measured for 50 nM unphosphorylated protein) were similar for R1275Q and F1174L ALK-TKD (Fig. 5G  and table S3) . However, at a more physiological ATP concentration of 2 mM, F1174L ALK-TKD was significantly less sensitive (P = 0.0128) to crizotinib inhibition (IC 50 = 130 nM) than R1275Q ALK-TKD (IC 50 = 84.6 nM). A similar difference was also seen with autophosphorylated proteins (table S4), as anticipated from Table 1 . Wild-type ALK-TKD resembled the F1174L variant in its relative insensitivity to crizotinib inhibition in vitro (tables S3 and S4), consistent with the finding that the drug does not inhibit growth of neuroblastoma cells that express wild-type ALK at normal levels (Figs. 1B and 2E). However, NB1 cells that express the receptor at very high levels because of an ALK amplification were sensitive to crizotinib (Figs. 1B and 2D ), indicating that inhibitor response may also be affected by issues of trafficking, subcellular localization, and expression level (19) .
The correlation between the increased ATP-binding affinity of F1174L-mutated ALK and its reduced sensitivity to crizotinib argues that this effect will be general, affecting the response to all ATP-competitive inhibitors. We tested this hypothesis with two other inhibitors. As shown in fig. S8 and table S5, in vitro inhibition of ALK-TKD by staurosporine is also impaired by the F1174L mutation compared with that seen for R1275Q-mutated ALK-TKD. Moreover, the ALK/insulin-like growth factor 1 receptor (IGF-1R)/IR inhibitor GSK1838705A (34) was substantially less effective at inducing cytotoxicity in neuroblastoma cell lines expressing F1174L ALK than those expressing R1275Q ALK (table S6) . Like crizotinib, GSK1838705A only showed significant in vivo activity against R1275Q xenografts ( fig. S9 ). These data, and the K m, ATP values reported in Table 1 , therefore suggest that F1174L-mutated ALK will be less sensitive to all ATP-competitive inhibitors.
Structural changes can explain the increased ATP-binding affinity in F1174L-mutated ALK Recent crystal structures of ALK-TKD (24, 26) revealed unexpected similarities with EGFR-TKD that are useful for understanding and predicting the consequences of ALK mutations. In the inactive ALK and EGFR TKD structures, key autoinhibitory interactions between the crucial aC helix and a short a helix at the beginning of the activation loop (magenta in Fig. 6 ) displace the aC helix from the position it must adopt in the "active" kinase. Intriguingly, the location of R1275 in ALK coincides closely with that of L837 in EGFR (L861 in pro-EGFR), where mutation to glutamine activates EGFR in NSCLC (35) . The R1275 side chain contributes directly to interactions between the magenta activation loop helix and the aC helix (Fig. 6B) , stabilizing the autoinhibited ALK-TKD conformation. Replacing R1275 with a glutamine, or phosphorylating nearby Y1278 in the activation loop (Fig. 6B) , will disrupt these autoinhibitory interactions and thus activate ALK.
F1174 lies at the C terminus of the aC helix (Fig. 6B) , and its side chain contributes to the small well-packed hydrophobic "core" between aC and the activation loop. A reduction in the size of the F1174 side chain will disrupt this packing, weakening autoinhibitory interactions and thus allowing ALK-TKD to adopt its active configuration. F1174 also makes another important interaction that may explain its effects on ATP binding. As shown in Fig. 6C, F1174 is in direct van der Waal's contact with F1271 of the crucial "DFG" motif, the aspartate of which (D1270) coordinates a Mg 2+ ion involved in ATP binding. Reducing the size of the F1174 side chain would remove one structural restraint on the DFG motif, which may allow D1270 to adopt a position with more optimal Mg 2+ coordination geometry, slightly increasing ATP-binding affinity (that is, reducing K m, ATP ). By contrast, crizotinib makes no interactions with the DFG motif (Fig. 6C , lower panel) and does not come within 4 Å of the D1270 side chain, so altering the DFG motif position should not affect crizotinib binding. These observations provide a structural hypothesis for how the F1174L mutation can increase the affinity of ALK-TKD for ATP without affecting its affinity for ATP-competitive inhibitors such as crizotinib, staurosporine, and GSK1838705A, leading to relative resistance. By contrast, the R1275 side chain is more than 7 Å away from the ATPbinding site, so its mutation should not directly affect ATP binding.
DISCUSSION
Genetic studies have firmly established ALK as a tractable molecular target in neuroblastoma, as well as several other human malignancies including NSCLC. We established here that neuroblastoma cell lines driven by ALK mutation or amplification were sensitive to crizotinib, an orally bioavailable ATP-competitive ALK inhibitor. Neuroblastoma cell lines and xenografts that express R1275Q-ALK, one of the two most commonly occurring mutations (12), were highly sensitive to crizotinib. By contrast, those expressing F1174L-mutated ALK (the other of the two most common mutations) were resistant to crizotinib in vitro and in vivo.
We showed that the reduced sensitivity of F1174L-expressing cell lines can be explained, at least in part, by an increased ATPbinding affinity compared with R1275Q, as manifested by K m, ATP values, and this reduces the potency of several ATP-competitive inhibitors. The R1275Q mutation in ALK resembles oncogenic EGFR mutations found in NSCLC, such as L834R (L858R in pro-EGFR), increasing both k cat and K m, ATP (36, 37) . By contrast, the F1174L mutation in ALK appears to combine the characteristics of an activating mutation and a resistance mutation, increasing k cat while maintaining a wild-type-like K m, ATP . The F1174L mutation thus resembles the drugresistant EGFR L834R/T766M double mutation (L858R/T790M in pro-EGFR) that has a reduced K m, ATP (33, 37) . The F1174L mutation has emerged not only as a builtin resistance mechanism in neuroblastoma as described here but also as an escape mechanism in ALK-translocated tumors treated with crizotinib (17) .
Despite the resistance described here, our results indicate that patients harboring the F1174L ALK mutation may benefit from treatment with ATP-competitive ALK inhibitors in some circumstances. For crizotinib itself, an increase in dosage to overcome the relative difference in K m, ATP compared with R1275Q-mutated ALK may be possible, although it remains unclear whether the exposures necessary to achieve the biochemical effect in tumor tissue will be achievable in the clinic. Crizotinib was well tolerated in adult patients with refractory lung cancer (15) , suggesting that a therapeutic window exists and that pediatric phase 1 studies should seek to define a true maximum tolerated dose in an effort to circumvent the de novo resistance caused by the F1174L mutation. The absence of an appropriate active-site cysteine precludes use of the irreversible inhibitor approach being investigated for EGFR (38) . Alternative strategies include development of therapeutic ALK antibody reagents for patients whose tumors harbor the F1174L mutation and/or ATP-competitive inhibitors that can overcome the K m, ATP effects by having higher affinity for ALK while retaining selectivity.
MATERIALS AND METHODS

In vitro tumor growth inhibition
In vitro crizotinib activity was evaluated in 18 neuroblastoma cell lines with the real-time cell electronic sensing (RT-CES) system (ACEA Biosciences). Cell lines were plated at 5000 to 30,000 cells per well depending on growth kinetics, and the drug was added at 1 to 10,000 nM after 24 hours. IC 50 was calculated from the cell index in triplicate samples after 72 hours of incubation. Growth inhibition at 333 nM crizotinib was calculated with the following formula: % inhibition = 100 × (cell index control − cell index treatment)/cell index control. Because of noncomparable maximum growth inhibition In vitro protein and phosphoprotein detection Each cell line was grown to 70 to 80% confluence, treated with crizotinib at the noted concentration (ranging from 0 to 10,000 nM) for 2 hours, and washed twice with ice-cold phosphate-buffered saline. Whole-cell lysates were then analyzed by immunoblotting as described (7) with antibodies to ALK (1:1000; Cell Signaling), pALK Tyr 1604 (1:1000; Cell Signaling), and actin (1:2000; Santa Cruz). Immunoblots were quantified with ImageJ (National Institutes of Health).
R E S E A R C H A R T I C L E
In vivo tumor growth inhibition CB17 scid female mice (Taconic Farms) were used to propagate subcutaneously implanted neuroblastoma tumors. Tumor diameters were measured twice per week with electronic calipers, and tumor volumes were calculated with the spheroid formula, (p/6)×d 3 , where d represents mean diameter. Once tumor volume exceeded 200 mm 3 , mice were randomized (n = 10 per arm) to receive crizotinib (100 mg/kg per dose) or vehicle (acidified water) daily by oral gavage for 4 weeks. Mice were maintained under protocols and conditions approved by our institutional animal care and use committee. Mice were killed when tumor volume exceeded 1500 mm 3 . A mixed-effects linear model was used to assess tumor volume over time between treatment and vehicle groups, controlling for tumor size at enrollment. Survival analysis was performed with the log-rank test with progression defined as tumor volume exceeding 1500 mm 3 or treatment-related death.
In vivo protein and phosphoprotein detection Mice harboring subcutaneously implanted NB1643 neuroblastoma tumors were randomized once tumor volume exceeded 300 mm 3 (n = 3 per arm) to receive crizotinib or vehicle as described above for 2 days. Mice were killed 4 hours after the final dose, and tumors were immediately snap-frozen in liquid nitrogen and pulverized for extraction of whole-cell lysates with 100 ml of extraction buffer (Invitrogen) containing protease inhibitor (Sigma), phosphatase inhibitors (Sigma), and phenylmethylsulfonyl fluoride. Lysates were sonicated, rotated for 1 hour at 4°C, and clarified by centrifugation. Protein concentration was normalized with the Bradford method, and lysates (200 mg) were subjected to immunoblotting as outlined above.
Recombinant protein expression and purification
A construct encoding ALK residues 1090 to 1416, together with an N-terminal hexahistidine tag, was used to express hexahistidinetagged recombinant ALK-TKDs in Sf9 cells as described in the Supplementary Methods.
Native gel kinase assays Native gel electrophoresis was used to monitor autophosphorylation progress for 10 mM ALK-TKD in 100 mM Hepes (pH 7.4), 150 mM NaCl, 2 mM dithiothreitol, 2 mM ATP, and 10 mM MgCl 2 , either free in solution or in the presence of lipid vesicles containing 10% DOGS-NTA-Ni (100 mM total lipid). Aliquots (10 ml) were taken at each time point, quenched by adding EDTA to 20 mM and placing on ice, and then subjected to electrophoresis on 7.5% tris-glycine native gels at 100 V for~14 hours. Gels were stained with Coomassie brilliant blue R-250.
Peptide phosphorylation assays Analysis of substrate phosphorylation by ALK-TKD used a peptide mimic of the ALK activation loop with the following sequence: biotin-ARDIYRASYYRKGGCAMLPVK (CanPeptide), referred to as YYY peptide (25) . Assay details (with Mg 2+ as divalent cation) and analysis of inhibition are described in the Supplementary Methods. Spontaneous autophosphorylation is negligible at the ALK-TKD concentrations used for assays. Fig. S8 . The F1174L mutation also increases IC 50 for staurosporine inhibition. Fig. S9 . The ALK/IGF-1R inhibitor GSK1838705A promotes regression of xenografts containing R1275Q mutations, but not F1174L or wild-type ALK. Table S1 . Effect of siRNA knockdown of ALK and Met on proliferation of neuroblastoma cell lines. Table S2 . Dependence of K m, ATP on peptide concentration for unphosphorylated ALK-TKD variants. Table S3 . Crizotinib inhibition of unphosphorylated ALK-TKD in vitro at two different ATP concentrations. Table S4 . IC 50 measurements for crizotinib inhibition of phosphorylated ALK-TKD variants (10 nM). Table S5 . IC 50 measurements for in vitro staurosporine inhibition of ALK-TKD variants. Table S6 Fig. S8 . The F1174L mutation also increases IC 50 for staurosporine inhibition. Fig. S9 . The ALK/IGF-1R inhibitor GSK1838705A promotes regression of xenografts containing R1275Q mutations, but not F1174L or wild-type ALK. Table S1 . Effect of siRNA knockdown of ALK and Met on proliferation of neuroblastoma cell lines. Table S2 . Dependence of K m, ATP on peptide concentration for unphosphorylated ALK-TKD variants. Table S3 . Crizotinib inhibition of unphosphorylated ALK-TKD in vitro at two different ATP concentrations. Table S4 . IC 50 measurements for crizotinib inhibition of phosphorylated ALK-TKD variants (10 nM). Table S5 . IC 50 measurements for in vitro staurosporine inhibition of ALK-TKD variants. Table S6 . IC 50 measurements for inhibition of neuroblastoma cell lines by the ALK/InsR/IGF-1R inhibitor GSK1838705A. References
SUPPLEMENTARY MATERIAL
SUPPLEMENTARY METHODS
DNA constructs and retrovirus production. Mutated and wild-type ALK cDNAs were cloned into the pCMV-XLS vector and subcloned into the retroviral vector MigR1, which also directs EGFP expression. Infection of retinal pigment epithelial cells (RPE1) that express telomerase (hTERT-RPE1) was performed as follows: Phoenix Ampho cells (Oribigen -RVC-10001) were plated ~ 500,000 cells in a 6 well plate in DMEM media with 10% FBS, 1% Pen/Strep, Gentamicin. Twenty-four hours after plating (~50% confluent), Phoenix cells were transfected with the ALK expression constructs using a 6:1 dilution of Fugene:plasmid DNA, and viruscontaining medium was harvested 48 hours later. hTERT-RPE1 cells were plated at ~500,000 cells per well in a 6 well plate, and growth medium was replaced with ʻvirus cocktailʼ (2 ml growth medium, 1ml filtered (0.45µm) viral media from Phoenix cells, 4µg/ml Polybrene (Santa Cruz)) and incubated overnight. Viral medium then replaced with fresh growth medium, and hTERT-RPE1 cells were incubated for 48 hours before sorting by flow cytometry for EGFPpositive cells.
Production and purification of recombinant ALK-TKD proteins.
DNA encoding ALK residues 1090-1416, together with an N-terminal hexahistidine tag, was subcloned into pFastBac-1 (Invitrogen) for expression of histidine-tagged recombinant ALKTKDs in Sf9 cells. Recombinant baculovirus was generated using the Bac-to-Bac system (Invitrogen). Sf9 cells were infected with recombinant virus for 3 days at 27˚C, harvested by centrifugation, and lysed by sonication. His-tagged protein was recovered from the lysis supernatant using NTA-Ni-agarose beads (Qiagen). After elution from NTA-Ni beads, ALK-TKD was dephosphorylated by incubation with 1µM YopH phosphatase (S1) for 12 hours at 4˚C to reverse spontaneous autophosphorylation that occurs within Sf9 cells during expression. ALK-TKD was then flowed over a cation exchange column (to remove YopH), exchanged into buffer containing 1M (NH 4 ) 2 SO 4 , and applied to a butyl sepharose column (GE Healthcare). Protein was eluted with a 20 column-volume linear gradient to 0M (NH 4 ) 2 SO 4 . ALK-TKD fractions were pooled and concentrated, and gel filtered using a Superdex 200 column (GE Healthcare) equilibrated in 25mM HEPES pH 7.4, 150mM NaCl, 4mM DTT. Mass spectrometry confirmed that dephosphorylation of the starting material was complete. Protein concentrations were determined by absorbance at 280nm using the calculated extinction coefficient 39440cm -1 M -1 . Phosphorylated ALK-TKD for peptide-based assays was produced in 100mM HEPES pH 7.4, 150mM NaCl, 2mM DTT,10mM MgCl 2 , 2mM ATP in the presence of lipid vesicles containing 10% DOGS-NTA-Ni (Avanti Polar Lipids) in a background of dioleoylphosphatidylcholine (Avanti Polar Lipids) prepared as described (S2) with a final concentration of 10µM DOGS-NTA-Ni (100µM total lipid). Full ALK-TKD autophosphosphorylation was achieved within 50mins (Fig.  4A, lower panel) under these conditions at 25˚C. Reactions were quenched where necessary by addition of EDTA to a final concentration of 20mM, followed by desalting under the conditions described above for gel filtration. EGFR-TKD was prepared as described (S2). Mass spectrometry-based phosphopeptide analysis confirmed that ALK-TKD autophosphorylation occurs at the expected sites within the activation loop, as well as additional sites.
In vitro protein and phosphoprotein detection. Each neuroblastoma cell line was cultured in ten T75 flasks under standard cell culture conditions. At 70-80% confluence crizotinib was added to cell culture medium to achieve a designated final concentration at one of nine doses ranging from 0nM to 10,000nM. Cells were incubated for 2 hours with drug, then collected, pelleted, and washed twice with ice cold phosphate-buffered saline (PBS). Whole cell lysates were then harvested, separated and immunoblotted as previously described (S3). The following antibodies were used, according to the supplierʼs instructions: anti-ALK (1:1,000; Cell Signaling, 3333), anti-phospho-ALK Tyr 1604 (1:1,000, Cell Signaling, 3341), anti-STAT3 (1:1,000; Cell Signaling, 9132), antiphospho-STAT3 Tyr 705 (1:1,000; Cell Signaling, 9145), anti-AKT (1:1,000; Cell Signaling, 9272), anti-phospho-AKT Ser 473 (1:1,000; Invitrogen, 44-621G), anti-p44/42 MAPK (ERK1/2) (1:1,000; Cell Signaling, 4695), anti-phospho-p44/42 MAPK (ERK 1/2) (1:1,000; Cell Signaling, 9101), antiactin (1:2,000; Santa Cruz, sc-1616).
Quantification of native gels.
Quantification of autophosphorylation progress employed ImageJ (NIH). Background was subtracted using a rollerball radius of 50 pixels. Using the gel analysis tool, the intensity of each band in the native gel was determined and normalized to the total intensity in each respective lane. Data were plotted as fraction of total intensity in each lane vs. reaction time.
Sedimentation equilibrium analytical ultracentrifugation. ALK-TKD proteins were diluted to 10 and 16.5µM in 25mM HEPES pH 7.4, 150mM NaCl, 2mM DTT, and subjected to sedimentation equilibrium ultracentrifugation at 13,000, 19,000, and 25,000 rpm in a Beckman Optima XL-A ultracentrifuge. Representative data from 13,000 rpm at 10µM are shown in fig. S5 . Data are plotted as ln(abs 280 ) vs (r 2 -r 0 2 )/2, where r is the radial distance of the sample and r 0 is the radial distance of the meniscus. The slope of the line is proportional to the weight-average molecular weight of the species in the sample. Data were analyzed using Sedphat (http://analyticalultracentrifugation.com).
Inhibitor profiling using commercially available kinase inhibitor screens. Kinase inhibitor screens containing 320 (overlapping) commercially available and wellcharacterized ATP-competitive inhibitors (Enzo Life Sciences ScreenWell and EMD InhibitorSelect Kinase Inhibitor Libraries 1-3) were used to compare the inhibitor selectivities of wild-type, R1275Q, and F1174L ALK-TKD. ALK TKD (2µM) was incubated with ATP (200µM, corresponding to the approximate K m,ATP of ALK-TKD at 10mM MgCl 2 ) in 96-well format with 50µM of each inhibitor (DMSO only in the negative control wells, or TAE-684 in the positive control wells) in a final reaction volume of 10µl. After incubation at room temperature, reactions were quenched with by adding EDTA to a final concentration of 20mM in 25mM HEPES pH 7.4, 150mM NaCl, 4mM DTT, and spotted onto nitrocellulose membranes in triplicate. Membranes were immunoblotted with anti-phosphotyrosine (PY20, 1:1000, Biomol), detecting with HRPconjugated α-mouse IgG (1:1000, GE Healthcare).
In vitro kinase assays. Analysis of substrate phosphorylation by ALK-TKD employed a peptide mimic of the ALK activation loop with sequence: biotin-ARDIYRASYYRKGGCAMLPVK (CanPeptide), referred to as YYY peptide (S4). Autophosphorylated ALK-TKD was used at 10nM in these assays, whereas unphosphorylated kinase was studied at 500nM (wild-type) or 50nM (R1275Q and F1174L), concentrations at which spontaneous autophosphorylation is negligible. Assays monitored incorporation of 32 P from γ-32 P ATP included in trace amounts (~20µCi per experiment) in the reactions. Comparisons with other peptides confirmed that peptide biotinylation does not affect kinetic parameters, and that reaction rates were linear with respect to both enzyme concentration and time under the assay conditions used ( fig. S3E,F) . Peptide concentrations were determined by absorbance at 280nm using a calculated extinction coefficient 3960cm
Assays were performed in 100mM HEPES pH 7.4, 150mM NaCl, 2mM DTT, 10mM MgCl 2, and 0.5mg/mL BSA at 25˚C, and were initiated by mixing equal volumes of solutions containing ALK-TKD and substrates respectively (at twice the desired final concentration). For determination of k cat and K m, peptide , peptide concentration was varied from 0 to 2mM, and ATP was saturating (2mM). For determination of K m, ATP , peptide was present at a fixed concentration of 1 or 2mM, and ATP was varied from 0.015625 to 2mM. Aliquots were taken at each time point, spotted onto pieces of phosphocellulose paper (Upstate Biotechnology), and immediately quenched with 0.5% phosphoric acid followed by extensive washing and drying with acetone. Incorporated radioactivity was measured by scintillation counting with appropriate background correction. Initial rates (determined at <10% product formation) were calculated using measured apparent γ-32 P ATP specific activity, normalized to enzyme concentration, and fit to the For experiments with added vesicles, which were prepared essentially as described (S2), the appropriate amount of vesicle solution (10µM DOGS-NTA-Ni, 100 or 200µM total lipid depending on the molar percentage of DOGS-NTA-Ni used) was added to the 2x protein mixture, and the reaction was performed and processed as above. Control experiments were performed with vesicles containing only dioleoylphosphatidylcholine (200µM total lipid). Enzyme concentration was held fixed at 1µM, with 2mM peptide and 2mM ATP present. Experiments using EGFR-TKD were performed with poly-Glu 4 Tyr (Sigma) instead of YYY peptide. Data are reported in Table 1 and tables S2-S5 as the mean of individual experiments (in at least triplicate) ± SEM. p values were determined using an unpaired t-test in GraphPad Prism 4.0.
In vitro analysis of ALK-TKD inhibition.
Inhibitor was added to the 2x substrate mixture prior to initiating reactions with ALK-TKD addition, so that final reactions represented a log 2 dilution series from 0 to 25,600nM inhibitor. Protein concentration was held at 50nM, and assays were performed as described above. The concentration of ʻYYYʼ peptide was held fixed at 0.5mM, and ATP was present at 0.2mM or 2mM. Background counts from a no-enzyme control were subtracted, the data were normalized to the 0nM inhibitor reaction and were fit to a sigmoidal dose-response (variable slope) equation in GraphPad Prism 4.0. Data are reported as means of individual experiments (in at least triplicate) ± SEM. p values were determined using an unpaired t-test in GraphPad Prism 4.0. Indicated cell lines were treated with the noted crizotinib concentrations and prepared for immunoblotting of whole cell lysates as described in Supplementary Methods. Diminution of pAkt levels approximately parallels that of ALK phosphorylation, with pAkt levels maximally reduced by ~100nM crizotinib in NB1 cells, ~333nM in NB1643 cells, but not until 10,000nM in SH-SY5Y cells. Substantial reduction of pSTAT3 levels requires higher crizotinib concentrations in all three cell lines, and pERK remains detectable even at 10,000nM crizotinib in NB1643 and SH-SY5Y cells. These data are consistent with previous reports that inhibition (or knockdown) of mutated ALK promotes apoptosis of neuroblastoma cell lines (S5). The differences in ʻsharpnessʼ of pAkt and pERK inhibition between NB1 and NB1643/SH-SY5Y cells appear to reflect receptor expression levels (which are very high in NB1). . Purified wild-type, F1174L, and R1275Q ALK-TKD were subjected to sedimentation equilibrium analytical ultracentrifugation to measure molecular weight and assess propensity to selfassociate (which might be affected by activating mutations). Proteins were centrifuged at three different speeds (13,000, 19,000 and 25,000 r.p.m.) at two different concentrations (10µM and 16.5µM). Efforts were made to globally fit data to models assuming either a single species or self-associating species, and best fits suggested a single species with molecular weight of 38.2kDa (wild-type), 42.4kDa (R1275Q) and 39.6kDa (F1174L). Data from representative experiments performed at 10µM ALK-TKD (at 13,000 r.p.m.) are plotted as ln(abs 280 ) against (r 2 -r o 2 )/2. This representation yields a straight line for a single species, with slope proportional to molecular weight. The data (and fits) suggest that -at concentrations in the 10-20µM rangeeach ALK-TKD variant is monomeric, excluding promotion of dimerization as a mechanism of TKD activation by these neuroblastoma mutations. The ability of staurosporine to inhibit ALK-TKD in vitro was analyzed as described for crizotinib in Figure 5 G and H. The IC 50 for staurosporine inhibition with 0.2mM ATP (A) is slightly higher for F1174L-mutated ALK-TKD than for the R1275Q variant (see table S5 ). As with crizotinib, this difference is enhanced when experiments were performed in the presence of 2mM ATP (B), more closely resembling cellular concentrations. All data are shown as the mean ± SEM from at least three independent experiments. The reduced K m,ATP for F1174L ALK-TKD also appears to increase IC 50 for staurosporine inhibition. GSK1838705A is another ATP-competitive ALK kinase inhibitor that also inhibits the insulin receptor and IGF 1R (S6). GSK1838705A also showed significant single agent activity against the NB1643 cell line (R1275Q) xenografted into CB17 scid -/-mice, but not against WT or F1174L xenografts. By contrast, the IGF 1R inhibitor GSK1904529A (S7) had no significant effect. Mice were randomized to GSK1838705A 60mg/kg/day once daily, GSK1904529A 30mg/kg/day once daily, or with vehicle (N=10/arm) following xenotransplantation and establishment of a tumor at 200 mm 3 . GSK1838705A caused complete regression of NB1643 xenografts within two weeks. Dosing was continued for a further two weeks, during which time tumors remained in macroscopic remission. Proliferation of the KELLY cell line harboring a F1174L mutation is inhibited by siRNA knockdown of ALK, but shows less inhibition with Met knockdown. The remaining three cell lines harbor wild-type normal copy number ALK. Cells were plated overnight and then transfected in triplicate with a pool of four siRNA targeting each kinase (Thermo Scientific Kinase siGenome Library), with positive (siPLK1) and negative (GAPD) controls. Substrate adherent growth was monitored for 100 hours using the Roche xCELLigence system. The area under the curve was calculated for each siRNA triplicate and mock transfection. % relative growth = AUC of the siKinase/AUC siControl. 
